These include AFQ056, an mGluR5 antagonist, which is being trialed in people with obsessive compulsive disorder who are resistant to selective serotonin reuptake inhibitors (Trial no. NCT01813019). Here, GRM5 is linked to obsessive-compulsive disorder.